中文摘要：

目的通过对CT抗原（cancer-testis antigen）KM-HN-1进行HLA-A＊0201限制性表位预测，并对候选表位肽与HLA-A＊0201分子结合亲和力及复合物稳定性进行分析，为探索基于KM-HN-1的免疫治疗奠定基础。方法利用基于蛋白酶体剪切位点特异性的算法PAProc及基于肽MHC-I结合的算法BIMAS和SYFPEITHI对KM-HN-1进行HLA-A＊0201限制性表位预测．合成KM-HN-1相关候选表位肽KM-HN-I321-329（KLLPFRETV），KM-HN-I303-211，（FLPTAPPNV），KM-HN-I629-637。（TLLQIIETV），KM-HN-I87-95（ILNKSIIEV），KM-HN-I538-596。（QMMEALDQL）及阳性对照肽HBVcAg18-27（FLPSDFFPSV）；对这些合成肽与HIA-A＊0201分子结合亲和力及其复合物稳定性根据文献报道的方法进行分析。结果KM-HN-I321-329（KLLPERETV）结合亲和力最低，KM-HN—I203-211（FLPTAPPNV）结合亲和力最高，其余3条肽结合亲和力介于2者之间；稳定性实验（DC50）结果显示：KM-HN-I538—546（QMMEALDQL）DC50小于2h，KM—HN-I321-329（KLLPERETV）的DC50介于2～4h之间，KM-HN-I87-95。（ILNKSIIEV）的DC50介于6～8h之间，KM-HN-I233-211（HLPTAPPNV）及KM-HN-I629—633（TLLQIIETV）的DC50均大于8h。结论基于蛋白酶体剪切位点特异性的算法及基于肽MHC-I结合的算法对KM-HN-1进行HLA-A＊0201限制性表位预测，结合候选表位肽与HLA-A＊0201分子结合的亲和力与复合物稳定性实验分析，为该抗原HLA-A＊0201限制性表位的鉴定奠定了基础。

英文摘要：

Objective To predict HLA-A ＊0201 restricted epitopes from cancer-testis （C-T） antigen KM-HN-1 and assay the HLA-A 0201 peptide binding ＆ complex stability of the predicted epitopes for developing cancer therapeutic vaccine based on KM-HN-1. Methods Proteasomal cleavage specificity based and peptide-MHC-I binding based algorithms were combined to predict HLA-A＊ 0201 restricted epitopes from antigen KM-HN-1. Peptide-MHC-I binding was predicted using 2 algorithms： BIMAS and SYFPEITHI. Proteasomal cleavage specificity was predicted using algorithm PAProc. The peptides were ranked for each algorithm and sorted by a cumulative score. Five candidate epitope peptides [KM-HN-I321-329（KLLPFRETV）, KM-HN-1203_2H （FLFFAPPNV）, KM-HN-I629-637 （TLLQIIETV）, KM-HN-I87-95 （ILNKSI- IEV）, and KM-HN-I538-546 （QMMEALDQL）] and positive control peptide were synthesized. Peptide HIA-A ＊ 0201 binding and complex stability was assayed following previously described methods. Results KM-HN-I321-329 （KLLPFRETV） showed the lowest HLA-A ＊ 0201 binding aflqnity among the 5 candidates, while KM-HN-I203-211 （FLFFAPPNV） was of the highest HLA-A ＊ 0201 binding aflqnity and the rest of the peptides showed intermediate binding aflqnity. The complex stability assay indicated that the dissociation complex 50 （DC50） for KM-HN-I538-546 （QMMEALDQL） was below 2 h, the DC50 for KM-HN-I32-329 （KLLPFRETV） was 2 - 6 h, the DC50. for KM-HN-I87-95 （ILNKSIIEV） was 6 - 8 h, and the DC50 for KM-HN-I203-211（FLFFAPPNV） and KM-HN-I629-637 （TLLQIIETV） were both above 8 h. Conclusion The prediction of HLA-A ＊ 0201 restricted epitopes from CF antigen KM-HN-1 and the peptide HLA-A ＊ 0201 binding aflqnity ＆ complex stability assay of the 5 candidate peptides provide experimental data for identification of HLA-A ＊ 0201 restricted epitopes from KM-HN-1.